Statin therapy improves brachial artery endothelial function in nephrotic syndrome  by Dogra, Gursharan K. et al.
Kidney International, Vol. 62 (2002), pp. 550–557
Statin therapy improves brachial artery endothelial function in
nephrotic syndrome
GURSHARAN K. DOGRA, GERALD F. WATTS, SUSAN HERRMANN, MARK A.B. THOMAS, and
ASHLEY B. IRISH
Department of Medicine and Western Australian Heart Research Institute, University of Western Australia, and Department of
Nephrology, Royal Perth Hospital, Perth, Western Australia, Australia
statins. The findings also suggest a role for dyslipidemia inStatin therapy improves brachial artery endothelial function
endothelial dysfunction and the risk for cardiovascular diseasein nephrotic syndrome.
in nephrotic syndrome.Background: Patients with nephrotic syndrome have impaired
endothelial function probably related to dyslipidemia. This
study evaluated the effects of statin therapy on dyslipidemia
and endothelial function in patients with nephrotic syndrome.
Patients with nephrotic syndrome have a 5.5-fold in-Methods: A sequential, open-label study of the effects of stat-
creased relative risk of myocardial infarction and a 2.8-foldins on endothelial dysfunction in 10 nephrotic patients treated
with an angiotensin-converting enzyme (ACE) inhibitor or an- increased relative risk of coronary death [1]. Possible etio-
giotensin II (Ang II) receptor antagonist. Endothelial function logical factors include hyperlipidemia, hypoalbuminemia
was assessed at baseline, after 12 weeks of treatment with and a hypercoagulable state [2], but their relative contribu-statins, and after an 8-week washout. Brachial artery endothe-
tion to cardiovascular risk remains uncertain. The rolelial function was measured as post-ischemic flow-mediated dila-
tion (FMD) using ultrasonography. Endothelium-independent, of hyperlipidemia, in particular increased low-density
glyceryl trinitrate-mediated vasodilation (GTNMD) also was lipoprotein (LDL) cholesterol, as a cardiovascular risk
measured. factor in the general population is well established [3].
Results: Serum lipids were significantly lower following
Both primary and secondary prevention studies of cho-statin: total cholesterol mean 8.2 0.4 (standard error) mmol/L
lesterol lowering with 3-hydroxy-3-methylglutaryl coen-versus 5.2 0.3 mmol/L, triglycerides 2.6  0.4 mmol/L versus
1.6  0.2 mmol/L, non-HDL-cholesterol 6.7  0.4 mmol/L zyme A reductase inhibitors (statins) demonstrate sig-
versus 3.7  0.2 mmol/L (all P  0.001). There was a trend to nificant risk reduction of coronary risk [4]. More recently,
an increase in serum albumin (31.0 1.3 g/L vs. 33.8 1.5 g/L; the importance of triglyceride-rich lipoproteins or non-P  0.078) and FMD improved significantly following treat-
high density lipoproteins in atherogenesis also has beenment (3.7  1.1% vs. 7.0  0.8%, P  0.01). After washout,
recognized [5, 6]. Although these studies may support aFMD deteriorated significantly to 3.5 1.4% (P 0.05) versus
week 12 FMD. GTNMD was unchanged. In multivariate re- role for lipid-modifying therapy in patients with nephro-
gression, reduction in non-high-density lipoprotein (HDL)- sis, there is no evidence that such therapy lowers cardio-
cholesterol ( - 0.736, P 0.027) and increase in serum albumin
vascular event rates in this population.( 0.723, P  0.028), but not the on-treatment level of non-
Endothelial dysfunction is an early phase of athero-HDL-cholesterol, were significant independent predictors of
improvement in FMD after adjusting for change in resting genesis, associated primarily with abnormal nitric oxide
brachial artery diameter. Changes in serum lipoprotein and physiology [7]. It can be detected non-invasively using
albumin concentrations off treatment were not associated with high-resolution ultrasonography to measure post-ische-deterioration in FMD.
mic flow-mediated dilation of conduit arteries [8]. Bra-Conclusion: Statin therapy significantly improves dyslipide-
chial artery endothelial dysfunction correlates with coro-mia and brachial artery endothelial function in patients with
nephrotic syndrome. Improvement in brachial artery endothe- nary endothelial dysfunction [9], cardiovascular risk
lial function may be in part related to a non-lipid effect of factors such as hypercholesterolemia and diabetes melli-
tus [10, 11] and predicts coronary events [12]. In ne-
phrotic syndrome, forearm microcirculatory endothelialKey words: nephrosis, HMGCoA reductase inhibitors, dyslipidemia,
cardiovascular disease, proteinuria, end-stage renal disease. function is impaired [13] possibly due to increased con-
tent of lysophosphatidylcholine (lysoPC) in LDL-choles-
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thelial function is impaired also in nephrotic syndrome An open-label sequential study design was used to
examine the effects of lipid-lowering therapy with ator-to a similar extent as in patients with primary hypercho-
lesterolemia matched for lipid and lipoprotein levels, vastatin on endothelial function. All patients had a
six-week run-in period during which they were off allsupporting an etiological role for nephrotic dyslipopro-
teinemia [15]. However, no study has determined the ef- lipid-lowering drugs and were advised to adhere to a
low-fat, low-cholesterol diet. Patients had endothelialfect of lipid-modifying therapy on endothelial dysfunc-
tion in nephrosis. function assessed at baseline, after 12 weeks on lipid-
lowering therapy and after an 8-week washout period.Nephrotic hyperlipidemia is characterized by increased
LDL as well as triglyceride-rich lipoproteins [16, 17]. The Patients were commenced on 10 mg of atorvastatin at
baseline, interim lipid levels were assessed after sixpossibility of increased oxidative stress as a consequence
of hypoalbuminemia [18] and increased pro-inflamma- weeks, and therapy was adjusted aiming for LDL-choles-
terol3.4 mmol/L and triglyceride1.8 mmol/L. Safetytory cytokines [19, 20] may be additive to the effects
of hyperlipidemia on cardiovascular risk in nephrosis. of therapy was assessed by clinical monitoring and labo-
ratory monitoring (liver and muscle enzyme determina-Lipid-modifying therapy with statins has been shown to
improve endothelial function in non-proteinuric popula- tions: alanine aminotransferase and creatine kinase) be-
fore and during treatment.tions [21–23]. Mechanisms involved include LDL-cho-
lesterol lowering as both oxidized LDL and naive LDL
Clinical and laboratory methodsreduce nitric oxide bioavailability [24, 25]. Furthermore,
statins exhibit pleiotropism and may improve endothelial All patients had a medical examination and 12-lead
electrocardiogram at study entry. Resting blood pressurefunction by their anti-inflammatory, anti-thrombogenic
and anti-oxidant effects [26, 27]. Statins also have sig- was measured using a Dinamap (Critikon Ltd., Tampa,
FL, USA). Patients provided 24-hour urine collectionsnificant triglyceride-rich lipoprotein lowering effects of
particular relevance to the mixed hyperlipidemia of ne- for measurement of protein excretion and creatinine
clearance. Venous blood samples were obtained after aphrotic syndrome [28]. Potentially statins could have a
profound influence on cardiovascular risk in this patient 12-hour fast and with minimal venous stasis. The bio-
chemical variables were measured by standard labora-population due to a combination of these effects. There-
fore, the aim of this study was to examine the effects of tory techniques unless otherwise stated. Serum LDL cho-
lesterol was calculated by the Friedewald equation, butlipid-lowering therapy with a statin on brachial artery
endothelial function in patients with nephrotic syn- was assayed directly with a commercial assay (LDL-C;
Boehringer Mannheim GmBH, Mannheim, Germany)drome. A secondary aim was to examine changes in
plasma lipoproteins and apolipoproteins and markers on a Hitachi 917 Biochemical Autoanalyzer (Hitachi Ltd,
Tokyo, Japan) in patients with triglyceride4.5 mmol/L.of inflammation to help identify mechanisms that may
contribute to endothelial dysfunction. Lipoprotein(a) [Lp(a)] and apolipoprotein B (apoB)
were assayed by immunonephelometric methods and
apolipoprotein C-III (apo C-III) using an immunoturbid-
METHODS
imetric assay. Non-HDL-cholesterol was derived from
Subjects and study design the equation (total cholesterol  HDL cholesterol).
C-reactive protein (CRP) was assayed using a high sensi-Fifteen patients aged 18 to 75 years who had nephrotic
syndrome with a primary glomerular disorder were re- tive immunonephelometric method (Dade Behring Mar-
burg GmbH, Marburg Germany). Tumour necrosiscruited from Perth renal clinics over a period of two years.
Patients with a serum creatinine 300 mol/L or signifi- factor-	 (TNF	) was measured using an immunometric
assay (Immulite TNF	; Diagnostic Products Corpora-cant deterioration in renal function in the past six
months, diabetes mellitus, malignancy, hypothyroidism, tion, Los Angeles, CA, USA). Interleukin-6 (IL-6) was
measured using a high sensitivity quantitative enzymesecondary cause for proteinuria, excess ethanol con-
sumption, macrovascular atherosclerotic disease, or pa- immunoassay (Quantikine HS; R&D Systems Inc.,
Minneapolis, MN, USA). The inter-assay coefficients oftients on aspirin, immunosuppressive therapy, including
steroids, allopurinol, fish oils, or multivitamin and anti- variation (CV) were all 6%.
oxidant vitamin preparations were excluded from the
Brachial artery ultrasonographystudy. One patient (Patient No. 3) was a smoker of 20
cigarettes/day. Patients were studied in an outpatient Brachial artery ultrasonography (Acuson Aspen 128
ultrasound device; Acuson Corporation, Mountain View,clinic setting and were not excluded if they were taking
angiotensin-converting enzyme inhibitors (ACEi) or a CA, USA) was carried out in patients after a 12-hour
fast and after resting supine for at least 15 minutes in astable dose of any other anti-hypertensive agent. The
Ethics Committee at Royal Perth Hospital approved the quiet, temperature controlled room (21 to 25
C). Endo-
thelium-dependent post-ischemic flow-mediated dilationstudy, and all volunteers gave written consent.
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Table 1. Baseline characteristics of nephrotic patients
Serum Serum Urinary Creatinine Disease
Age creatinine albumin protein clearance duration
Patient no. years Sex lmol/L g/L g/24 h mL/min Glomerular histology months
1 38 M 137 40 1.39 73.5 Focal and segmental glomerulonephritis 48
2 67 F 89 26 6.43 103.8 Membranous glomerulonephritis 5
3 33 F 67 32 1.0 43.5 Mesangiocapillary glomerulonephritis type 1 156
4 38 F 185 31 8.02 35.7 Focal and segmental glomerulonephritis 36
5 69 M 154 26 14.95 66.7 No biopsy 2
6 56 F 70 26 6.92 108.1 Mesangioproliferative glomerulonephritis 6
7 72 M 271 33 3.7 27.2 No biopsy 24
8 43 M 90 33 1.39 140.4 Membranous glomerulonephritis 12
9 63 M 135 28 3.27 21.0 Focal and segmental glomerulonephritis 24
10 33 F 44 35 3.4 198.9 Focal and segmental glomerulonephritis 24
Mean 51.2 124.2 31.0 5.0 81.9 33.7
SD 15.8 67.9 4.6 4.3 56.7 45.4
(FMD) and endothelium-independent glyceryl trinitrate vastatin for the treatment of severe mixed hyperlipid-
emia was required, and one withdrew for psychosocial(GTN) mediated dilation (GTNMD) were measured us-
ing methods described elsewhere [11, 15, 29] and ana- reasons. Ten patients completed the study, of whom nine
were on atorvastatin (median 20 mg/day, range 20 tolyzed by two experienced observers using edge-detection
software validated within our department [29]. Doppler 40) and one was converted to simvastatin 40 mg/day
following development of an urticarial rash related toflow velocity and flow rate (mL/min) were determined
commencing atorvastatin. One patient (Patient No. 1),during baseline scanning and during the first 15 seconds
although nephrotic at screening with a diagnosis of focalof reactive hyperemia. Maximal FMD and GTNMD re-
and segmental glomerulonephritis on renal biopsy, wassponses were calculated as % change in brachial artery
in partial disease remission for the duration of the study.diameter from baseline. The analytical (intra-observer)
This patient was included in our previous study [15] andCV of the computerized technique in our hands is in
this study, since moderate proteinuria, dyslipidemia andthe order of 6.7%. The CV for repeated within-subject
endothelial dysfunction persisted, and complete remis-measurement was 14.7% (N  24) with a mean  stan-
sion did not occur. FMD was studied at baseline, afterdard deviation (SD) difference in FMD of 1.6  1.0%.
12 weeks of statin and after an 8-week washout. GTNMD
Statistical analysis was studied in all patients at baseline and in only five
out of the ten patients at subsequent visits due to patientAnalyses were performed using SPSS v.10.0 (Statisti-
refusal or medical unsuitability related to hypotension.cal Package for Social Sciences; SPSS Inc., Chicago, IL,
We have previously shown GTNMD is unimpaired inUSA). Results are expressed as mean  SD for descrip-
patients with nephrotic syndrome compared with healthytive data and mean  SE for comparative data. Skewed
controls [15].variables were log transformed prior to analysis and
Table 1 shows the baseline characteristics, includingare presented as geometric mean (95% confidence in-
glomerular histology and renal function of the ten pa-terval; 95% CI). Repeated measures analysis of variance
tients that completed the study. Patients had a mean age(r-ANOVA) was used to compare data at baseline, after
of 51.2 15.8 years and half were men. Two patients didstatin and at the end of washout. If the r-ANOVA was
not have a biopsy-proven diagnosis for the study dura-significant (P  0.05), paired t tests were performed with
tion. Median disease duration was 24 months (range 2Bonferroni adjustment for a three-way comparison. Lin-
to 156). Patients had nephrotic range proteinuria 5.0 ear regression analysis was used to identify significant
4.3 g/day with hypoalbuminemia 31.0  4.6 g/L and se-correlations between changes in FMD and other bio-
rum creatinine 124.2 67.9 mol/L. Eight patients werechemical variables.
on ACE-I (perindopril 2, trandolapril 2, quinapril 1, ena-
lapril 1, captopril 1, lisinopril 1) and the remainder were
RESULTS on an Ang II receptor antagonist (irbesartan), the doses
Of the 15 patients entered in the study, two patients of which were unaltered through the study.
were withdrawn as they went into spontaneous complete Table 2 shows the changes in blood pressure, renal
remission within six weeks of commencing lipid-lowering function, serum glucose and indices of nephrosis with
therapy, one patient commenced high-dose prednisolone statin therapy and following washout. Body weight, sys-
for minimal change glomerulonephritis, one was with- tolic and diastolic blood pressure, serum creatinine, cre-
atinine clearance and serum glucose were not signifi-drawn as a combination of gemfibrozil, fish oil and ator-
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Table 2. Clinical and biochemical characteristics of nephrotic patients pre-statin, following statin therapy and post-statin
ANOVA
Parameters Pre-statin Statin Post-statin P value
Weight kg 69.94.4 70.64.5 70.64.2 0.685
SBP mm Hg 129.56.5 133.37.4 126.74.0 0.479
DBP mm Hg 74.52.8 77.54.5 74.62.4 0.623
Serum creatinine lmol/L 124.221.5 131.625.3 133.726.1 0.244
Creatinine clearance mL/min 81.917.9 89.315.6 88.414.9 0.587
Serum albumin g/L 31.01.3 33.81.5 33.81.8 0.069
Urinary proteina g/24 h 3.7 (2.0–6.8) 3.2 (1.9–5.7) 2.6 (1.3–5.0) 0.123
Serum glucose mmol/L 5.20.3 5.20.3 5.10.2 0.785
Mean  standard error shown except a geometric mean (95% confidence interval).
Abbreviations are: SBP systolic blood pressure; DBP diastolic blood pressure.
Table 3. Blood lipids, lipoproteins and markers of inflammation in nephrotic patients pre-statin, following statin therapy and post-statin
ANOVA
Parameters Pre-statin Statin Post-statin P value
Total cholesterol mmol/L 8.20.4a 5.20.3b 7.70.5 0.001
LDL-cholesterol mmol/L 5.50.4a 3.00.3b 4.80.4 0.001
HDL-cholesterole mmol/L 1.4 (1.1–1.7)a 1.4 (1.1–1.8) 1.3 (1.0–1.6) 0.027
Triglyceridese mmol/L 2.3 (1.6–3.4)a 1.5 (1.1–2.1)c 2.8 (1.8–4.2) 0.001
Non-HDL-cholesterol mmol/L 6.70.4a 3.70.2b 6.30.5 0.001
ApoB g/L 1.60.1a 1.00.05b 1.50.1 0.001
Lp(a)e g/L 0.39 (0.17–0.87)d 0.24 (0.09–0.62) 0.17 (0.06–0.46) 0.002
ApoCIIIe g/L 0.2 (0.16–0.26)a 0.18 (0.15–0.22)d 0.23 (0.19–0.29) 0.001
CRPe mg/L 1.3 (0.7–2.1) 1.2 (0.7–2.1) 1.0 (0.5–2.2) 0.763
IL-6e pg/mL 3.0 (1.8–4.8) 2.9 (2.0–4.1) 2.4 (1.4–4.0) 0.297
TNF-	 pg/mL 5.00.8 4.70.8 5.10.8 0.656
Mean  standard error shown except egeometric (e geometric) mean (95% confidence interval).
Abbreviations are: LDL, low-density lipoprotein; HDL, high-density lipoprotein; ApoB, apolipoprotein B; Lp(a), lipoprotein(a); ApoCIII, apolipoprotein CIII;
CRP, C-reactive protein; IL-6, interleukin-6; TNF-	, tumor necrosis factor-	.
a P not significant compared to post-statin
b P  0.001 compared to pre-statin and post-statin
c P  0.01 compared to pre-statin and post-statin
d P  0.01 compared to post-statin
e geometric
cantly different among the three study visits. There was statistically significant change in CRP, IL-6 or TNF	
with statin treatment or at the end of washout.a non-significant trend to an increase in serum albumin
(r-ANOVA, P  0.069) and a non-significant reduction Statin therapy was well tolerated by the group, and
there were no complaints of gastrointestinal intolerancein 24-hour protein excretion over the 20-week study pe-
riod (r-ANOVA  0.123). or myalgias at the doses employed. Muscle enzyme, cre-
atine kinase (CK), did not change significantly amongChanges in serum lipids and lipoproteins are shown
in Table 3. Overall, lipid-lowering therapy resulted in a visits (pre-statin 116.8  23.3 U/L, statin 151.0  31.4
U/L, post-statin 113.5  21.2 U/L; r-ANOVA, P significant reduction in total cholesterol, LDL-choles-
terol, non-HDL-cholesterol, apoB and triglycerides (all 0.110). The liver enzyme alanine amino transferase
(ALT) increased significantly on treatment (pre-statinP  0.001). The increase in HDL-cholesterol did not
reach statistical significance. There was a non-significant 18.7  1.8 U/L, statin 29.5  3.6 U/L, post-statin 22.3 
4.2 U/L; r-ANOVA, P  0.034). Only two patients hadreduction in apoC-III (P  0.09) with statin therapy but
a significant increase in apoC-III (P  0.01) following ALT levels above the laboratory reference range (nor-
mal 36 U/L) with the highest ALT reached beingwashout. Lp(a) was not significantly reduced with lipid-
lowering therapy, but at washout it was significantly 50 U/L, and two patients had asymptomatic elevations
of CK above the laboratory reference range (normallower than at baseline (P  0.01; Table 3). Except for
Lp(a), none of the washout serum lipid and lipoprotein 200 U/L) with the highest CK reached being 316 U/L.
Results of brachial ultrasonography and post-ischemiclevels were significantly different to baseline values. Ex-
clusion of the patient receiving simvastatin does not alter FMD are shown in Figure 1 and Table 4. Baseline bra-
chial artery diameter, basal Doppler blood flow, andthese results significantly. Table 3 also shows changes in
inflammatory markers with statin therapy. There was no hyperemic Doppler blood flow values were not signifi-
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FMD (regression coefficient 2.4  1.0,  0.663; P 
0.063) and increase in serum albumin during statin ther-
apy (regression coefficient 0.6  0.2,  0.737; P  0.040;
model adjusted R2  0.57). The fall in FMD during
washout was not significantly associated with any of the
predictor variables, including increase in non-HDL-cho-
lesterol off statin therapy.
DISCUSSION
To our knowledge this is the first study to examine
the effects of statin therapy on vascular function in pa-
tients with nephrotic syndrome. There was a significant
improvement in flow-mediated dilation of the brachial
artery, a measure of endothelial function, with statin
therapy in eight of the ten nephrotic patients studied.
Fig. 1. Post-ischemic flow-mediated dilation (FMD) in nephrotic pa- The remaining two patients had preserved basal FMD
tients pre-statin, following statin therapy and post-statin. The P value refers responses off treatment and showed minimal change into repeated measures ANOVA; horizontal bars represent mean FMD.
FMD with statin therapy. Furthermore, this improve-
ment in brachial FMD was significantly correlated with
reduction in non-HDL-cholesterol achieved with statin
cantly different between visits. Post-ischemic FMD in- therapy. These findings support the hypothesis that dys-
creased significantly on lipid-lowering therapy (pre- lipidemia contributes to increased risk for cardiovascular
statin 3.7  1.1%, statin 7.0  0.8%, post-statin 3.5  disease [1] and endothelial dysfunction [15] in nephrotic
1.4%; r-ANOVA, P  0.002; P  0.013 between pre- patients.
statin and statin; P  0.039 between statin and post- Plasma lipid abnormalities in the nephrotic syndrome
statin; P  1.0 between pre- and post-statin). Exclusion are a consequence of a combination of increased synthe-
of the patient in partial remission (Patient No. 1) did not sis and reduced clearance [30, 31]. They consist of in-
alter the significant change in FMD with statin treatment creased concentrations of total cholesterol and apoB
(pre-statin 4.0  1.1%, statin 7.2  0.8%, post-statin containing lipoproteins, namely LDL cholesterol, as well
3.9  1.4%; r-ANOVA P  0.007, N  9). GTNMD as raised triglycerides particularly in those patients with
was not significantly different on statin therapy (pre- heavier proteinuria and severe hypoalbuminemia [16, 32].
statin 16.8  1.0%, statin 15.1  1.5%; paired t test, P  More recently, elevated triglyceride-rich lipoproteins
0.467). (TRL) including very low-density (VLDL) and interme-
In univariate regression, only reduction in non-HDL- diate-density lipoproteins (IDL), and apolipoprotein
cholesterol with statin therapy (regression coefficient C-III (apoC-III), a remnant lipoprotein marker, have
1.9  1.0,  0.560, P  0.092) and increase in serum been reported as elevated in nephrotic patients [17, 33].
albumin (regression coefficient 0.5  0.2,  0.552, P  Although LDL cholesterol is recognized as the predomi-
0.098) showed a trend to an association with improve- nant lipid-related cardiovascular risk factor [3], recent
ment in FMD. None of the other predictor variables evidence supports a role for triglyceride-rich lipoproteins
[either change in, or absolute levels achieved on statin as well [5, 6, 34]. In our study, statin therapy was associ-
therapy, of LDL-cholesterol, triglycerides, apoB, Lp(a), ated with a significant reduction in apoB containing lipo-
proteinuria, or inflammatory markers] were significantly proteins as well as non-HDL-cholesterol that includes
associated with improvement in FMD. In multivariate LDL-cholesterol, as well as TRL’s and apoC-III con-
regression, both reduction in non-HDL-cholesterol with taining lipoproteins. Furthermore, reduction in non-
statin therapy (P 0.027) and increase in serum albumin HDL-cholesterol was a significant independent predictor
during 12 weeks of statin therapy (P  0.028) indepen- of improvement in endothelial function as measured by
dently and significantly predicted improvement in FMD FMD, implying a collective role for VLDL, IDL and
after adjusting for changes in resting brachial artery di- LDL-cholesterol in inducing endothelial dysfunction and
ameter (model adjusted R2 0.58; Table 5). While exclu- the increased risk of cardiovascular disease in nephrotic
sion of the patient in partial remission (Patient No. 1) syndrome.
limits multivariate regression due to small sample size, A further finding of our study was that absolute levels
the regression model continues to show a significant of non-HDL-cholesterol obtained on treatment did not
trend for an association between change in non-HDL significantly predict improvement in FMD and the in-
crease in non-HDL-cholesterol in the post-statin periodcholesterol with statin treatment and improvement in
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Table 4. Blood flow, resting brachial artery diameter and post-ischemic flow-mediated dilation (FMD) in nephrotic patients pre-statin, on
statin therapy and following post-statin
ANOVA
Parameters Pre-statin Statin Post-statin P value
Resting brachial artery diameter mm 3.70.2 3.70.3 3.80.3 0.247
Basal Doppler blood flow mL/min 131.425.6 118.116.9 172.412.8 0.108
Hyperemic Doppler blood flow mL/min 743.3151.1 722.7136.4 721.280.9 0.975
FMD % 3.71.1 7.00.8 3.51.4 0.002
Data are mean  standard error.
Table 5. Multivariate regression model showing association between improvement in brachial FMD and reduction in non-HDL-cholesterol
and increase in serum albumin during statin therapy, adjusted for change in resting brachial artery diameter
Regression coefficient Standardized
Predictor variable (standard error) coefficient  P value
Reduction in non-HDL-cholesterol mmol/L 2.6 (0.9) 0.736 0.027
Increase in serum albumin g/L 0.6 (0.2) 0.723 0.028
Change in resting brachial artery diameter 5.2 (2.6) 0.563 0.098
Adjusted R2  0.58. Abbreviations are: HDL, high-density lipoprotein; FMD, post-ischemic flow-mediated dilation.
did not predict fall in FMD, suggesting an additional which is known to inhibit acetylcholine-mediated relax-
ation of cultured endothelial cells [14]. It is possible thatnon-lipid mediated effect of statin therapy on endothelial
function. Statins are known to have a wide range of an increase in serum albumin as a consequence of partial
disease remission contributes to improvement in FMDpleiotropic effects beyond lipid-lowering that may con-
tribute to improved vascular function and cardiovascular by these anti-oxidant mechanisms or by mechanisms re-
lated to its vasorelaxant and nitric oxide binding proper-outcomes [26, 35]. This pleiotropism includes up-regula-
tion of nitric oxide synthase and anti-oxidant, anti- ties [39]. Partial remission of nephrosis may marginally
improve dyslipidemia thereby contributing to improvedinflammatory or anti-thrombotic effects [26, 27, 35–37].
The development of endothelial dysfunction on with- FMD. However, decrease in serum concentrations of
Lp(a), also shown to be associated with disease remissiondrawal of statins in our study supports mechanisms that
involve functional changes, such as improved nitric oxide [31], were not a significant predictor of improvement
in FMD. Furthermore, in the post-statin period FMDbioavailability, in preference to structural changes in the
arterial wall. This mechanism also is suggested by studies deteriorated significantly in the absence of a significant
deterioration of serum albumin concentration. This sug-showing early rapid improvement in endothelial function
with statins [22, 38]. Although statin therapy was not as- gests a minimal contributory role for serum albumin in
nephrotic endothelial dysfunction.sociated with significant changes in inflammatory mark-
ers previously shown to be elevated in NS (such as TNF	 We have previously shown that GTNMD is unim-
paired in nephrotic syndrome [15] and in this study[19]), our sample size was small and does not allow us
to rule out a role for pleiotropic effects. Hence, the pre- GTNMD did not change with statin therapy in five pa-
tients. This suggests that the improvement in FMD withcise mechanisms by which statins improve vascular func-
tion in nephrotic syndrome remain to be determined. statin therapy in nephrotic patients specifically repre-
sents enhanced endothelial function, which in conduitWe have previously shown that nephrotic patients ex-
hibit endothelial dysfunction compared with normoal- arteries is felt to be predominantly nitric oxide mediated
[40, 41]. Endothelial dysfunction itself is an early riskbuminemic, normolipidemic controls, but that serum
albumin is not a significant predictor of endothelial dys- marker for cardiovascular disease [7, 8] and improved
nitric oxide bioavailability has anti-atherogenic effectsfunction [15]. An unexpected finding of the present study
was the significant independent correlation between im- [7]. Furthermore, impaired brachial and coronary endo-
thelial function predicts future risk for coronary eventsprovement in FMD and increase in serum albumin dur-
ing statin therapy. This increase in serum albumin was [12, 42, 43]. These studies support the concept that im-
proving endothelial dysfunction with statin therapyassociated with a decrease in proteinuria and is consistent
with a trend to disease remission with time. Nephrotic should reduce the known cardiovascular risk associated
with nephrotic syndrome. However, the prospectivehypoalbuminemia is associated with reduced plasma
anti-oxidant potential [18] and an increased content of studies showing increased coronary events in subjects
with impaired FMD also showed impaired GTNMD inlysophosphatidylcholine (lysoPC) in LDL-cholesterol,
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